Cognitive Control Mechanisms in Older Adults

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age65+
SponsorHebrew University of Jerusalem

About this trial

The prevalence of depressive symptoms in older adults is on the rise, affecting 13 to 37% of older adults globally. These symptoms significantly impact health, increasing the risk of dementia and cognitive decline, and impairing daily functioning and quality of life. Reduced cognitive control (CC) is a key factor contributing to depressive symptoms, affecting 40% of adults with such symptoms. Despite this, over half of affected adults do not respond well to available treatments. Computerized cognitive training (CCT) has shown efficacy in improving CC but its impact on daily functioning is limited. The Cognitive Orientation to Occupational Performance (CO-OP) approach has demonstrated promise in improving daily functioning, as measured by occupational performance (OP). We propose a novel intervention, GOLD-Cog+, combining CCT and CO-OP, to address CC and functional deficits in older adults with depressive symptoms.

Eligibility criteria

Qualifiers

Depressive Symptoms based on Patient Health Questionnaire (PHQ-8) ≥ 5

Healthy Cognition based on Montreal Cognitive Assessment (MoCa) ≥ 20

Capable of signing and agreeing to participate in the study

Have the basic technological skills to use a tablet based on self-report

Disqualifiers

Any neurodegenerative disorder (e.g., Mild Cognitive Impairment (MCI), Dementia, Parkinson's disease) via self-report

Psychiatric disorders, not including depression or anxiety disorders (specifically: Schizophrenia, Bipolar or Psychotic disorders) via self-report

Trial design

Treatments tested in this trial

  • GOLD-Cog+

Treatment groups

42 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Hebrew University of Jerusalem

Lead sponsor

University of Melbourne

Collaborator